SK1182003A3 - Compounds and compositions for delivering active agents - Google Patents

Compounds and compositions for delivering active agents Download PDF

Info

Publication number: SK1182003A3
Authority: SK; Slovakia
Prior art keywords: active agent; insulin; composition; hormone; compound
Prior art date: 2000-06-29

Application number

SK118-2003A

Other languages

English (en)

Slovak (sk)

Inventor

John Weidner

Bruce F Variano

Shingai Majuru

Sataj Bhankarkar

William E Bay

Lynn Shields

Original Assignee

Emisphere Tech Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-06-29

Filing date

2001-06-29

Publication date

2003-09-11

2001-06-29 Application filed by Emisphere Tech Inc filed Critical Emisphere Tech Inc

2003-09-11 Publication of SK1182003A3 publication Critical patent/SK1182003A3/sk

Links

239000013543 active substance Substances 0.000 title claims abstract description 85
150000001875 compounds Chemical class 0.000 title claims abstract description 74
239000000203 mixture Substances 0.000 title claims abstract description 65
238000000034 method Methods 0.000 claims abstract description 16
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 59
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 44
241001465754 Metazoa Species 0.000 claims description 34
102000004877 Insulin Human genes 0.000 claims description 32
108090001061 Insulin Proteins 0.000 claims description 32
229940125396 insulin Drugs 0.000 claims description 30
239000007787 solid Substances 0.000 claims description 28
150000003839 salts Chemical class 0.000 claims description 24
102000014150 Interferons Human genes 0.000 claims description 18
108010050904 Interferons Proteins 0.000 claims description 18
239000000122 growth hormone Substances 0.000 claims description 16
239000002775 capsule Substances 0.000 claims description 15
229940079322 interferon Drugs 0.000 claims description 14
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 13
IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 claims description 13
108090000765 processed proteins & peptides Proteins 0.000 claims description 13
229910052708 sodium Inorganic materials 0.000 claims description 13
239000011734 sodium Substances 0.000 claims description 13
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 12
229920000669 heparin Polymers 0.000 claims description 12
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 11
229960000265 cromoglicic acid Drugs 0.000 claims description 11
229940088597 hormone Drugs 0.000 claims description 11
239000005556 hormone Substances 0.000 claims description 11
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 10
102000003982 Parathyroid hormone Human genes 0.000 claims description 10
108090000445 Parathyroid hormone Proteins 0.000 claims description 10
229960001319 parathyroid hormone Drugs 0.000 claims description 10
239000000199 parathyroid hormone Substances 0.000 claims description 10
102000004196 processed proteins & peptides Human genes 0.000 claims description 10
229960002897 heparin Drugs 0.000 claims description 9
239000012634 fragment Substances 0.000 claims description 8
101000976075 Homo sapiens Insulin Proteins 0.000 claims description 7
BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 claims description 7
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 claims description 7
229940127215 low-molecular weight heparin Drugs 0.000 claims description 7
238000002156 mixing Methods 0.000 claims description 7
239000008363 phosphate buffer Substances 0.000 claims description 7
239000012453 solvate Substances 0.000 claims description 7
239000003826 tablet Substances 0.000 claims description 7
102000055006 Calcitonin Human genes 0.000 claims description 6
108060001064 Calcitonin Proteins 0.000 claims description 6
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 6
239000007788 liquid Substances 0.000 claims description 6
239000002904 solvent Substances 0.000 claims description 6
241000283690 Bos taurus Species 0.000 claims description 5
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical compound [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 5
108090000394 Erythropoietin Proteins 0.000 claims description 5
102000003951 Erythropoietin Human genes 0.000 claims description 5
102000018997 Growth Hormone Human genes 0.000 claims description 5
108010051696 Growth Hormone Proteins 0.000 claims description 5
102000002265 Human Growth Hormone Human genes 0.000 claims description 5
108010000521 Human Growth Hormone Proteins 0.000 claims description 5
239000000854 Human Growth Hormone Substances 0.000 claims description 5
229940105423 erythropoietin Drugs 0.000 claims description 5
DNIAPMSPPWPWGF-UHFFFAOYSA-N monopropylene glycol Natural products CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 5
235000015277 pork Nutrition 0.000 claims description 5
OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 5
239000000843 powder Substances 0.000 claims description 5
239000003488 releasing hormone Substances 0.000 claims description 5
101800000414 Corticotropin Proteins 0.000 claims description 4
229920002683 Glycosaminoglycan Polymers 0.000 claims description 4
108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 4
239000004599 antimicrobial Substances 0.000 claims description 4
229960004015 calcitonin Drugs 0.000 claims description 4
229960000258 corticotropin Drugs 0.000 claims description 4
IDLFZVILOHSSID-OVLDLUHVSA-N corticotropin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(N)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)NC(=O)[C@@H](N)CO)C1=CC=C(O)C=C1 IDLFZVILOHSSID-OVLDLUHVSA-N 0.000 claims description 4
150000004676 glycans Chemical class 0.000 claims description 4
229940047124 interferons Drugs 0.000 claims description 4
229920001184 polypeptide Polymers 0.000 claims description 4
229920001282 polysaccharide Polymers 0.000 claims description 4
239000005017 polysaccharide Substances 0.000 claims description 4
235000000346 sugar Nutrition 0.000 claims description 4
229920002567 Chondroitin Polymers 0.000 claims description 3
PMATZTZNYRCHOR-CGLBZJNRSA-N Cyclosporin A Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims description 3
229930105110 Cyclosporin A Natural products 0.000 claims description 3
108010036949 Cyclosporine Proteins 0.000 claims description 3
229920000045 Dermatan sulfate Polymers 0.000 claims description 3
108010029961 Filgrastim Proteins 0.000 claims description 3
102000012673 Follicle Stimulating Hormone Human genes 0.000 claims description 3
108010079345 Follicle Stimulating Hormone Proteins 0.000 claims description 3
108010017544 Glucosylceramidase Proteins 0.000 claims description 3
102000004547 Glucosylceramidase Human genes 0.000 claims description 3
102100039619 Granulocyte colony-stimulating factor Human genes 0.000 claims description 3
229920001499 Heparinoid Polymers 0.000 claims description 3
101000741445 Homo sapiens Calcitonin Proteins 0.000 claims description 3
102000014429 Insulin-like growth factor Human genes 0.000 claims description 3
102000006992 Interferon-alpha Human genes 0.000 claims description 3
108010047761 Interferon-alpha Proteins 0.000 claims description 3
102000000589 Interleukin-1 Human genes 0.000 claims description 3
108010002352 Interleukin-1 Proteins 0.000 claims description 3
102000005157 Somatostatin Human genes 0.000 claims description 3
108010056088 Somatostatin Proteins 0.000 claims description 3
102000036693 Thrombopoietin Human genes 0.000 claims description 3
108010041111 Thrombopoietin Proteins 0.000 claims description 3
108010059993 Vancomycin Proteins 0.000 claims description 3
GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 claims description 3
108010004977 Vasopressins Proteins 0.000 claims description 3
102000002852 Vasopressins Human genes 0.000 claims description 3
239000000427 antigen Substances 0.000 claims description 3
108091007433 antigens Proteins 0.000 claims description 3
102000036639 antigens Human genes 0.000 claims description 3
KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 claims description 3
230000001746 atrial effect Effects 0.000 claims description 3
229960003773 calcitonin (salmon synthetic) Drugs 0.000 claims description 3
229960001265 ciclosporin Drugs 0.000 claims description 3
239000003086 colorant Substances 0.000 claims description 3
229930182912 cyclosporin Natural products 0.000 claims description 3
229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 3
239000007884 disintegrant Substances 0.000 claims description 3
229960004177 filgrastim Drugs 0.000 claims description 3
229940028334 follicle stimulating hormone Drugs 0.000 claims description 3
239000002554 heparinoid Substances 0.000 claims description 3
229940025770 heparinoids Drugs 0.000 claims description 3
229940045644 human calcitonin Drugs 0.000 claims description 3
150000002632 lipids Chemical class 0.000 claims description 3
239000000314 lubricant Substances 0.000 claims description 3
229940094443 oxytocics prostaglandins Drugs 0.000 claims description 3
239000002245 particle Substances 0.000 claims description 3
239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
239000004014 plasticizer Substances 0.000 claims description 3
229920001223 polyethylene glycol Polymers 0.000 claims description 3
235000013772 propylene glycol Nutrition 0.000 claims description 3
150000003180 prostaglandins Chemical class 0.000 claims description 3
102000004169 proteins and genes Human genes 0.000 claims description 3
108090000623 proteins and genes Proteins 0.000 claims description 3
108010068072 salmon calcitonin Proteins 0.000 claims description 3
NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 3
229960000553 somatostatin Drugs 0.000 claims description 3
229960003165 vancomycin Drugs 0.000 claims description 3
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 claims description 3
229960003726 vasopressin Drugs 0.000 claims description 3
DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 claims description 2
108010002350 Interleukin-2 Proteins 0.000 claims description 2
102000000588 Interleukin-2 Human genes 0.000 claims description 2
239000002202 Polyethylene glycol Substances 0.000 claims description 2
238000004519 manufacturing process Methods 0.000 claims description 2
150000004682 monohydrates Chemical class 0.000 claims 3
239000006186 oral dosage form Substances 0.000 claims 3
101001011741 Bos taurus Insulin Proteins 0.000 claims 2
VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 claims 2
102000003996 Interferon-beta Human genes 0.000 claims 2
108090000467 Interferon-beta Proteins 0.000 claims 2
102000008070 Interferon-gamma Human genes 0.000 claims 2
108010074328 Interferon-gamma Proteins 0.000 claims 2
IXIBAKNTJSCKJM-BUBXBXGNSA-N bovine insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@@H](C)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 IXIBAKNTJSCKJM-BUBXBXGNSA-N 0.000 claims 2
229910052804 chromium Inorganic materials 0.000 claims 2
239000011651 chromium Substances 0.000 claims 2
229940044627 gamma-interferon Drugs 0.000 claims 2
229940047135 glycate Drugs 0.000 claims 2
239000003102 growth factor Substances 0.000 claims 2
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 claims 2
JDJALSWDQPEHEJ-LMVCGNDWSA-N x4853 Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 JDJALSWDQPEHEJ-LMVCGNDWSA-N 0.000 claims 2
NOESYZHRGYRDHS-ZYCCASTOSA-N 8a-l-threonine-10a-l-isoleucine-insulin Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 NOESYZHRGYRDHS-ZYCCASTOSA-N 0.000 claims 1
101000993800 Sus scrofa Insulin Proteins 0.000 claims 1
239000003963 antioxidant agent Substances 0.000 claims 1
230000003078 antioxidant effect Effects 0.000 claims 1
235000006708 antioxidants Nutrition 0.000 claims 1
229940107218 chromium Drugs 0.000 claims 1
201000010099 disease Diseases 0.000 claims 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
239000002552 dosage form Substances 0.000 claims 1
229960005375 lutein Drugs 0.000 claims 1
239000001656 lutein Substances 0.000 claims 1
235000012680 lutein Nutrition 0.000 claims 1
KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 claims 1
ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 claims 1
CEYGNZMCCVVXQW-UHFFFAOYSA-N phosphoric acid;propane-1,2-diol Chemical compound CC(O)CO.OP(O)(O)=O CEYGNZMCCVVXQW-UHFFFAOYSA-N 0.000 claims 1
229940119528 pork insulin Drugs 0.000 claims 1
229940083542 sodium Drugs 0.000 claims 1
KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 claims 1
FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 claims 1
238000002360 preparation method Methods 0.000 abstract description 9
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 81
239000000243 solution Substances 0.000 description 64
238000006243 chemical reaction Methods 0.000 description 40
239000011541 reaction mixture Substances 0.000 description 33
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 28
235000002639 sodium chloride Nutrition 0.000 description 19
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 18
OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
238000003756 stirring Methods 0.000 description 18
239000008367 deionised water Substances 0.000 description 15
229910021641 deionized water Inorganic materials 0.000 description 15
210000002966 serum Anatomy 0.000 description 15
239000003795 chemical substances by application Substances 0.000 description 14
229940124447 delivery agent Drugs 0.000 description 13
238000010992 reflux Methods 0.000 description 13
WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 12
YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
150000001413 amino acids Chemical class 0.000 description 12
210000004369 blood Anatomy 0.000 description 12
239000008280 blood Substances 0.000 description 12
239000011521 glass Substances 0.000 description 11
229910052757 nitrogen Inorganic materials 0.000 description 11
238000010438 heat treatment Methods 0.000 description 9
159000000000 sodium salts Chemical class 0.000 description 9
QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 8
230000004888 barrier function Effects 0.000 description 8
239000000706 filtrate Substances 0.000 description 8
-1 polyoxyethylene Polymers 0.000 description 8
XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 6
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
229940125904 compound 1 Drugs 0.000 description 6
239000000839 emulsion Substances 0.000 description 6
210000003238 esophagus Anatomy 0.000 description 6
125000000896 monocarboxylic acid group Chemical group 0.000 description 6
239000012071 phase Substances 0.000 description 6
239000011550 stock solution Substances 0.000 description 6
239000000725 suspension Substances 0.000 description 6
238000003828 vacuum filtration Methods 0.000 description 6
238000005303 weighing Methods 0.000 description 6
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 5
LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 5
239000002253 acid Substances 0.000 description 5
239000012298 atmosphere Substances 0.000 description 5
238000004821 distillation Methods 0.000 description 5
239000008103 glucose Substances 0.000 description 5
239000000047 product Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
238000012360 testing method Methods 0.000 description 5
GCVGCXMTCJMBHY-UHFFFAOYSA-N 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoic acid Chemical compound OC(=O)CCCNC(=O)C1=CC=C(Cl)C=C1O GCVGCXMTCJMBHY-UHFFFAOYSA-N 0.000 description 4
206010002091 Anaesthesia Diseases 0.000 description 4
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 4
150000001408 amides Chemical class 0.000 description 4
230000037005 anaesthesia Effects 0.000 description 4
210000001367 artery Anatomy 0.000 description 4
ZPEIMTDSQAKGNT-UHFFFAOYSA-N chlorpromazine Chemical compound C1=C(Cl)C=C2N(CCCN(C)C)C3=CC=CC=C3SC2=C1 ZPEIMTDSQAKGNT-UHFFFAOYSA-N 0.000 description 4
229960001076 chlorpromazine Drugs 0.000 description 4
239000002532 enzyme inhibitor Substances 0.000 description 4
RIFGWPKJUGCATF-UHFFFAOYSA-N ethyl chloroformate Chemical compound CCOC(Cl)=O RIFGWPKJUGCATF-UHFFFAOYSA-N 0.000 description 4
238000004128 high performance liquid chromatography Methods 0.000 description 4
210000004283 incisor Anatomy 0.000 description 4
229960003299 ketamine Drugs 0.000 description 4
239000010410 layer Substances 0.000 description 4
238000003825 pressing Methods 0.000 description 4
238000005070 sampling Methods 0.000 description 4
GCVGCXMTCJMBHY-UHFFFAOYSA-M 4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O GCVGCXMTCJMBHY-UHFFFAOYSA-M 0.000 description 3
LWXFCZXRFBUOOR-UHFFFAOYSA-N 4-chloro-2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1O LWXFCZXRFBUOOR-UHFFFAOYSA-N 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
108010039627 Aprotinin Proteins 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 3
241000282693 Cercopithecidae Species 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
229910021529 ammonia Inorganic materials 0.000 description 3
229910052791 calcium Inorganic materials 0.000 description 3
239000011575 calcium Substances 0.000 description 3
238000004364 calculation method Methods 0.000 description 3
239000003153 chemical reaction reagent Substances 0.000 description 3
238000004587 chromatography analysis Methods 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
239000003814 drug Substances 0.000 description 3
210000001035 gastrointestinal tract Anatomy 0.000 description 3
239000011777 magnesium Substances 0.000 description 3
239000004570 mortar (masonry) Substances 0.000 description 3
239000002831 pharmacologic agent Substances 0.000 description 3
229920001308 poly(aminoacid) Polymers 0.000 description 3
125000006239 protecting group Chemical group 0.000 description 3
UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 3
UQFYDAAKCZKDHS-UHFFFAOYSA-M sodium;4-[(4-chloro-2-hydroxybenzoyl)amino]butanoate Chemical compound [Na+].OC1=CC(Cl)=CC=C1C(=O)NCCCC([O-])=O UQFYDAAKCZKDHS-UHFFFAOYSA-M 0.000 description 3
238000013222 sprague-dawley male rat Methods 0.000 description 3
238000002604 ultrasonography Methods 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
AZUYLZMQTIKGSC-UHFFFAOYSA-N 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one Chemical compound ClC=1C(=C2C=NNC2=CC=1C)C=1C(=NN(C=1C)C1CC2(CN(C2)C(C=C)=O)C1)C=1C=C2C=NN(C2=CC=1)C AZUYLZMQTIKGSC-UHFFFAOYSA-N 0.000 description 2
QZFDCCAPLFBSGM-UHFFFAOYSA-N 2-amino-5-(4-chloro-2-hydroxyphenyl)-5-oxopentanoic acid Chemical compound OC(=O)C(N)CCC(=O)C1=CC=C(Cl)C=C1O QZFDCCAPLFBSGM-UHFFFAOYSA-N 0.000 description 2
NXRFMWBOQWRGFW-UHFFFAOYSA-N 4-chloro-2-hydroxybenzamide Chemical compound NC(=O)C1=CC=C(Cl)C=C1O NXRFMWBOQWRGFW-UHFFFAOYSA-N 0.000 description 2
KJWJQOMPJKFLKL-UHFFFAOYSA-N 7-chloro-1,3-benzoxazine-2,4-dione Chemical compound O1C(=O)NC(=O)C=2C1=CC(Cl)=CC=2 KJWJQOMPJKFLKL-UHFFFAOYSA-N 0.000 description 2
FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 2
IAZDPXIOMUYVGZ-UHFFFAOYSA-N DMSO Substances CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
238000005481 NMR spectroscopy Methods 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
241000288906 Primates Species 0.000 description 2
241000700159 Rattus Species 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000000654 additive Substances 0.000 description 2
239000002671 adjuvant Substances 0.000 description 2
125000001931 aliphatic group Chemical group 0.000 description 2
150000001412 amines Chemical class 0.000 description 2
125000003277 amino group Chemical group 0.000 description 2
239000008346 aqueous phase Substances 0.000 description 2
238000003149 assay kit Methods 0.000 description 2
239000002585 base Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000000872 buffer Substances 0.000 description 2
WESLSUXBZGCBOK-UHFFFAOYSA-N butyl 4-chloro-2-hydroxybenzoate Chemical compound CCCCOC(=O)C1=CC=C(Cl)C=C1O WESLSUXBZGCBOK-UHFFFAOYSA-N 0.000 description 2
LEMUFSYUPGXXCM-JNEQYSBXSA-N caninsulin Chemical compound [Zn].C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC3N=CN=C3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1C=NC=N1 LEMUFSYUPGXXCM-JNEQYSBXSA-N 0.000 description 2
PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
150000001732 carboxylic acid derivatives Chemical class 0.000 description 2
230000000295 complement effect Effects 0.000 description 2
238000007865 diluting Methods 0.000 description 2
238000012377 drug delivery Methods 0.000 description 2
238000000921 elemental analysis Methods 0.000 description 2
CXVQSUBJMYZELD-UHFFFAOYSA-N ethyl 4-aminobutanoate;hydrochloride Chemical compound [Cl-].CCOC(=O)CCC[NH3+] CXVQSUBJMYZELD-UHFFFAOYSA-N 0.000 description 2
125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
239000012065 filter cake Substances 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
235000019634 flavors Nutrition 0.000 description 2
239000011888 foil Substances 0.000 description 2
238000005194 fractionation Methods 0.000 description 2
229910052739 hydrogen Inorganic materials 0.000 description 2
238000003018 immunoassay Methods 0.000 description 2
239000003112 inhibitor Substances 0.000 description 2
238000012528 insulin ELISA Methods 0.000 description 2
239000004026 insulin derivative Substances 0.000 description 2
239000003055 low molecular weight heparin Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
238000002844 melting Methods 0.000 description 2
230000008018 melting Effects 0.000 description 2
239000012044 organic layer Substances 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000000144 pharmacologic effect Effects 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
230000002685 pulmonary effect Effects 0.000 description 2
238000001953 recrystallisation Methods 0.000 description 2
230000011514 reflex Effects 0.000 description 2
DCKVNWZUADLDEH-UHFFFAOYSA-N sec-butyl acetate Chemical compound CCC(C)OC(C)=O DCKVNWZUADLDEH-UHFFFAOYSA-N 0.000 description 2
229910052938 sodium sulfate Inorganic materials 0.000 description 2
235000011152 sodium sulphate Nutrition 0.000 description 2
239000012265 solid product Substances 0.000 description 2
150000008163 sugars Chemical class 0.000 description 2
229940124597 therapeutic agent Drugs 0.000 description 2
229940108519 trasylol Drugs 0.000 description 2
238000005292 vacuum distillation Methods 0.000 description 2
229910052725 zinc Inorganic materials 0.000 description 2
239000011701 zinc Substances 0.000 description 2
FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
150000005207 1,3-dihydroxybenzenes Chemical class 0.000 description 1
DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 description 1
UPXRTVAIJMUAQR-UHFFFAOYSA-N 4-(9h-fluoren-9-ylmethoxycarbonylamino)-1-[(2-methylpropan-2-yl)oxycarbonyl]pyrrolidine-2-carboxylic acid Chemical compound C1C(C(O)=O)N(C(=O)OC(C)(C)C)CC1NC(=O)OCC1C2=CC=CC=C2C2=CC=CC=C21 UPXRTVAIJMUAQR-UHFFFAOYSA-N 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
241000972773 Aulopiformes Species 0.000 description 1
241000271566 Aves Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
108010016626 Dipeptides Proteins 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
108700012941 GNRH1 Proteins 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 1
241000238631 Hexapoda Species 0.000 description 1
241000282412 Homo Species 0.000 description 1
102000004218 Insulin-Like Growth Factor I Human genes 0.000 description 1
239000000232 Lipid Bilayer Substances 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
241000282567 Macaca fascicularis Species 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
108010076181 Proinsulin Proteins 0.000 description 1
108020004511 Recombinant DNA Proteins 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
229930006000 Sucrose Natural products 0.000 description 1
CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
241000282887 Suidae Species 0.000 description 1
238000002835 absorbance Methods 0.000 description 1
238000005903 acid hydrolysis reaction Methods 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
XJLATMLVMSFZBN-VYDXJSESSA-N actinonin Chemical compound CCCCC[C@H](CC(=O)NO)C(=O)N[C@@H](C(C)C)C(=O)N1CCC[C@H]1CO XJLATMLVMSFZBN-VYDXJSESSA-N 0.000 description 1
XJLATMLVMSFZBN-UHFFFAOYSA-N actinonine Natural products CCCCCC(CC(=O)NO)C(=O)NC(C(C)C)C(=O)N1CCCC1CO XJLATMLVMSFZBN-UHFFFAOYSA-N 0.000 description 1
239000012042 active reagent Substances 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000003863 ammonium salts Chemical class 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
238000010171 animal model Methods 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940121375 antifungal agent Drugs 0.000 description 1
239000003429 antifungal agent Substances 0.000 description 1
229960004405 aprotinin Drugs 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
239000012455 biphasic mixture Substances 0.000 description 1
230000008499 blood brain barrier function Effects 0.000 description 1
230000023555 blood coagulation Effects 0.000 description 1
230000036765 blood level Effects 0.000 description 1
210000001218 blood-brain barrier Anatomy 0.000 description 1
239000012267 brine Substances 0.000 description 1
230000005587 bubbling Effects 0.000 description 1
239000006227 byproduct Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
230000001055 chewing effect Effects 0.000 description 1
235000013330 chicken meat Nutrition 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
238000001816 cooling Methods 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
230000001186 cumulative effect Effects 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
230000003292 diminished effect Effects 0.000 description 1
LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
229910000397 disodium phosphate Inorganic materials 0.000 description 1
235000019800 disodium phosphate Nutrition 0.000 description 1
239000002270 dispersing agent Substances 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
229940079593 drug Drugs 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
XBPOBCXHALHJFP-UHFFFAOYSA-N ethyl 4-bromobutanoate Chemical compound CCOC(=O)CCCBr XBPOBCXHALHJFP-UHFFFAOYSA-N 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000011049 filling Methods 0.000 description 1
238000001914 filtration Methods 0.000 description 1
235000003599 food sweetener Nutrition 0.000 description 1
150000003948 formamides Chemical class 0.000 description 1
238000009472 formulation Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
235000011389 fruit/vegetable juice Nutrition 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
239000007903 gelatin capsule Substances 0.000 description 1
150000002334 glycols Chemical class 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
239000007924 injection Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
229910003480 inorganic solid Inorganic materials 0.000 description 1
230000000968 intestinal effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
238000004255 ion exchange chromatography Methods 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229960004184 ketamine hydrochloride Drugs 0.000 description 1
239000002502 liposome Substances 0.000 description 1
238000004811 liquid chromatography Methods 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000845 maltitol Substances 0.000 description 1
235000010449 maltitol Nutrition 0.000 description 1
VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
229940035436 maltitol Drugs 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000004005 microsphere Substances 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
235000019796 monopotassium phosphate Nutrition 0.000 description 1
210000004877 mucosa Anatomy 0.000 description 1
GVOISEJVFFIGQE-YCZSINBZSA-N n-[(1r,2s,5r)-5-[methyl(propan-2-yl)amino]-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](N(C)C(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 GVOISEJVFFIGQE-YCZSINBZSA-N 0.000 description 1
OHDXDNUPVVYWOV-UHFFFAOYSA-N n-methyl-1-(2-naphthalen-1-ylsulfanylphenyl)methanamine Chemical compound CNCC1=CC=CC=C1SC1=CC=CC2=CC=CC=C12 OHDXDNUPVVYWOV-UHFFFAOYSA-N 0.000 description 1
239000002736 nonionic surfactant Substances 0.000 description 1
239000004006 olive oil Substances 0.000 description 1
235000008390 olive oil Nutrition 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002894 organic compounds Chemical class 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000000575 pesticide Substances 0.000 description 1
239000002953 phosphate buffered saline Substances 0.000 description 1
PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
239000012066 reaction slurry Substances 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
238000004366 reverse phase liquid chromatography Methods 0.000 description 1
235000019515 salmon Nutrition 0.000 description 1
230000007017 scission Effects 0.000 description 1
230000035945 sensitivity Effects 0.000 description 1
238000007086 side reaction Methods 0.000 description 1
229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
235000017557 sodium bicarbonate Nutrition 0.000 description 1
229910000029 sodium carbonate Inorganic materials 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 1
239000007909 solid dosage form Substances 0.000 description 1
239000007790 solid phase Substances 0.000 description 1
239000000600 sorbitol Substances 0.000 description 1
230000000087 stabilizing effect Effects 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007858 starting material Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000005720 sucrose Substances 0.000 description 1
QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
230000009747 swallowing Effects 0.000 description 1
239000003765 sweetening agent Substances 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-N vancomycin Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C(O)=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)NC)[C@H]1C[C@](C)(N)[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-N 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH], i.e. somatotropin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Epidemiology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Endocrinology (AREA)
Zoology (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Engineering & Computer Science (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

SK118-2003A 2000-06-29 2001-06-29 Compounds and compositions for delivering active agents SK1182003A3 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US21489300P	2000-06-29	2000-06-29
PCT/US2001/021073 WO2002002509A1 (fr)	2000-06-29	2001-06-29	Composes et compositions pour l'administration de principes actifs

Publications (1)

Publication Number	Publication Date
SK1182003A3 true SK1182003A3 (en)	2003-09-11

Family

ID=22800813

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
SK118-2003A SK1182003A3 (en)	2000-06-29	2001-06-29	Compounds and compositions for delivering active agents

Country Status (24)

Country	Link
US (1)	US7351741B2 (fr)
EP (1)	EP1299348B1 (fr)
JP (1)	JP2004521857A (fr)
KR (1)	KR100828668B1 (fr)
CN (1)	CN100482637C (fr)
AT (1)	ATE391708T1 (fr)
AU (3)	AU2001273153B2 (fr)
BR (1)	BR0112311A (fr)
CA (1)	CA2411754C (fr)
CY (1)	CY1108532T1 (fr)
CZ (1)	CZ303736B6 (fr)
DE (1)	DE60133555T2 (fr)
DK (1)	DK1299348T3 (fr)
ES (1)	ES2306719T3 (fr)
HK (1)	HK1054918A1 (fr)
IL (1)	IL153297A0 (fr)
MX (1)	MXPA02012855A (fr)
NZ (1)	NZ523017A (fr)
PT (1)	PT1299348E (fr)
RU (1)	RU2326110C2 (fr)
SK (1)	SK1182003A3 (fr)
UA (1)	UA80248C2 (fr)
WO (1)	WO2002002509A1 (fr)
ZA (1)	ZA200209946B (fr)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6358504B1 (en) *	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
JP4879433B2 (ja)	2000-01-13	2012-02-22	エミスフェアー・テクノロジーズ・インク	活性剤を送達するための化合物および組成物
DE60134245D1 (de) *	2000-09-06	2008-07-10	Emisphere Tech Inc	(5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
US20040259952A1 (en) *	2001-11-29	2004-12-23	Richat Abbas	Formulations for oral administration of cromolyn sodium
US20030198666A1 (en) *	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
ES2412306T3 (es) *	2002-01-09	2013-07-11	Emisphere Technologies, Inc.	Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
AU2003208945B2 (en)	2002-02-20	2008-05-01	Emisphere Technologies, Inc	Method for administering GLP-1 molecules
CA2511530C (fr) *	2003-01-06	2013-07-09	Emisphere Technologies, Inc.	Therapie d'administration orale d'insuline le soir
AU2004220544B2 (en) *	2003-03-06	2010-06-17	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
JP2006519881A (ja) *	2003-03-06	2006-08-31	エミスフィアーテクノロジーズインコーポレイテッド	経口インスリン治療及びプロトコール
MXPA06001353A (es)	2003-08-08	2006-05-04	Abgenix Inc	Anticuerpos dirigidos a hormona paratiroides(pth) y usos de los mismos.
US7318925B2 (en) *	2003-08-08	2008-01-15	Amgen Fremont, Inc.	Methods of use for antibodies against parathyroid hormone
DE602004006279T2 (de)	2003-08-20	2007-12-27	Eli Lilly And Co., Indianapolis	Verbindungen, verfahren und formulierungen zur oralen verabreichung einer glucagonartigen peptid (glp)-1-verbindung oder eines melanocortin-4-rezeptor-(mc4-)agonistschen peptids
CA2532026C (fr)	2003-08-20	2012-04-17	Eli Lilly And Company	Composes, procedes et preparations destines a l'apport oral d'un compose peptidique de type glucagon (glp-1) ou d'un peptide agoniste du recepteur 4 de melanocortine (mc4)
US20050203001A1 (en)	2004-03-05	2005-09-15	Emisphere Technologies, Inc.	Oral insulin therapies and protocol
US20090029911A1 (en) *	2003-09-25	2009-01-29	Ashley Martin Williams	Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
US20060286129A1 (en)	2003-12-19	2006-12-21	Emisphere Technologies, Inc.	Oral GLP-1 formulations
EP1750729A2 (fr)	2004-05-06	2007-02-14	Emisphere Technologies, Inc.	Forme de dosage solide d'heparine mouillee
RU2530889C2 (ru) *	2004-05-14	2014-10-20	Эмисфире Текнолоджис, Инк.	Соединения и составы для доставки активных веществ
KR101299707B1 (ko) *	2004-05-14	2013-08-28	에미스페어 테크놀로지스, 인코포레이티드	활성제 전달용 화합물 및 조성물
JP4995080B2 (ja)	2004-05-14	2012-08-08	エミスフェアー・テクノロジーズ・インク	活性薬剤を送達するためのアリールケトン化合物および組成物
US20080132527A1 (en)	2004-05-19	2008-06-05	Emisphere Technologies, Inc.	Compositions For Delivering Acyclovir
CN1968704B (zh)	2004-05-19	2010-12-08	爱密斯菲尔科技公司	局部用色甘酸制剂
CN101014360A (zh)	2004-08-03	2007-08-08	埃米斯菲尔技术公司	抗糖尿病口服胰岛素－双胍组合物
JP4636839B2 (ja) *	2004-09-24	2011-02-23	パナソニック株式会社	電子デバイス
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
GB0427603D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
EP1830831B1 (fr)	2004-12-29	2015-01-21	Emisphere Technologies, Inc.	Formulations pharmaceutiques contenant des sels de gallium
US8110547B2 (en) *	2005-01-12	2012-02-07	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
US8975227B2 (en)	2005-07-15	2015-03-10	Emisphere Technologies, Inc.	Intraoral dosage forms of glucagon
AU2006312117A1 (en) *	2005-11-04	2007-05-18	Genta Incorporated	Pharmaceutical gallium compositions and methods
WO2007121318A2 (fr)	2006-04-12	2007-10-25	Emisphere Technologies, Inc.	Préparations destinées à l'administration d'insuline
US8771712B2 (en)	2006-05-09	2014-07-08	Emisphere Technologies, Inc.	Topical administration of acyclovir
WO2008003050A2 (fr)	2006-06-28	2008-01-03	Emisphere Technologies, Inc.	Formulations de nitrate de gallium
USRE48164E1 (en)	2006-08-31	2020-08-18	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
CA2681158C (fr)	2007-03-13	2018-09-18	Nutrition 21, Inc.	Procedes et compositions utilises pour la liberation prolongee de chrome
WO2009002867A2 (fr)	2007-06-26	2008-12-31	Nutrition 21, Inc.	Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
CA2701482C (fr) *	2007-10-08	2018-10-23	Lux Biosciences, Inc.	Compositions ophtalmiques comprenant des inhibiteurs de la calcineurine ou des inhibiteurs de mtor
IL188647A0 (en) *	2008-01-08	2008-11-03	Orina Gribova	Adaptable structured drug and supplements administration system (for oral and/or transdermal applications)
ES2616231T3 (es)	2008-08-21	2017-06-12	Immunogenics Llc	Formulación para administración oral de proteínas
US9017725B2 (en) *	2009-06-09	2015-04-28	Aurinia Pharmaceuticals Inc.	Topical drug delivery systems for ophthalmic use
CA2767342C (fr)	2009-07-09	2018-05-01	Oshadi Drug Administration Ltd.	Compositions de support matriciel, procedes et utilisations
EP2461803B1 (fr)	2009-08-03	2018-10-17	Emisphere Technologies, Inc.	Composition de naproxène à action rapide avec effets gastro-intestinaux réduits
US20110177147A1 (en) *	2010-01-21	2011-07-21	General Electric Company	Stable biocidal delivery systems
WO2011097148A2 (fr) *	2010-02-04	2011-08-11	Parsons Lowell C	Utilisation de préparations orales à base d'héparine pour traiter des maladies et des états pathologiques du tractus urinaire
JP5894726B2 (ja) *	2010-07-13	2016-03-30	株式会社大塚製薬工場	膵島の分離方法および膵島組織を保護するための保護液
JP6152346B2 (ja)	2011-03-01	2017-06-21	ジェーディーエスセラピューティックス、エルエルシーＪＤＳＴｈｅｒａｐｅｕｔｉｃｓ，ＬＬＣ	糖尿病、低血糖、および関連障害の治療および予防のためのインスリンとクロムの組成物
RU2495866C1 (ru) *	2012-06-19	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации	Производное гамма-аминомасляной кислоты, обладающее ноотропной активностью в сочетании с транквилизирующим действием
RU2495867C1 (ru) *	2012-07-11	2013-10-20	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации"	Дилитиевая соль n-салицилоилглицина, обладающая ноотропной активностью
CN104884065B (zh)	2012-09-21	2019-01-01	强烈治疗剂公司	治疗癌症的方法
AP2015008746A0 (en)	2013-04-29	2015-09-30	Univ Bonn	Compositions and methods for altering second messenger signaling
US11865121B2 (en)	2016-02-11	2024-01-09	Nutrition21, LLC	Chromium containing compositions for improving health and fitness
RU2633769C1 (ru) *	2016-05-16	2017-10-18	Государственное бюджетное образовательное учреждение высшего профессионального образования "Волгоградский государственный медицинский университет" Министерства здравоохранения Российской Федерации ГБОУ ВПО ВолгГМУ МЗ РФ	Гамма-(N-гидроксибензоиламино)бутирохлориды, как полупродукты для получения потенциальных биологически активных производных гамма-аминомасляной кислоты
US20190224275A1 (en)	2017-05-12	2019-07-25	Aurinia Pharmaceuticals Inc.	Protocol for treatment of lupus nephritis
CN108689876B (zh) *	2018-06-28	2020-11-27	苏州东南药业股份有限公司	一种8-(2-羟基苯甲酰胺基)辛酸钠的制备方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR4446E (fr)	1904-07-05	1905-08-25	Jacques Pinatel	Étau serrant les pièces coniques
US3489793A (en)	1966-05-16	1970-01-13	Francia Formaceutici S R L	New benzamido butyric acid derivatives
ES369853A1 (es)	1969-07-24	1971-07-16	Bama S A Lab	Procedimiento para la obtencion de derivados del acido ep- silon-amino-caproico.
DE2260118C2 (de)	1972-12-08	1982-06-03	Bayer Ag, 5090 Leverkusen	Penicilline sowie ihre Verwendung als Arzneimittel
DE2517229A1 (de)	1975-04-18	1976-10-28	Boehringer Mannheim Gmbh	Phenylalkylcarbonsaeure-derivate und verfahren zu ihrer herstellung
NZ196349A (en)	1980-03-07	1984-08-24	Interx Research Corp	Enhancement of absorption rate of orally administered polar bioactive agents
US4442090A (en)	1980-11-09	1984-04-10	Kyoto Yakuhin Kogyo Kabushiki Kaisha	Absorption-promoting compounds, compositions thereof with pharmaceuticals and/or bases for rectal administration and method of use
US4900730A (en)	1981-01-14	1990-02-13	Toyo Jozo Co., Ltd.	Preparation which promotes the absorption of peptides
GB2092136B (en)	1981-01-17	1985-06-05	Mitsui Toatsu Chemicals	Production of n-substituted amide compounds
JPS58140026A (ja)	1982-01-14	1983-08-19	Toyo Jozo Co Ltd	吸収性良好な製剤
CA1188987A (fr)	1981-03-06	1985-06-18	Masataka Morishita	Preparation ayant d'excellentes qualites d'absorption
DE3266360D1 (en)	1981-06-16	1985-10-24	Choay Sa	Medicines containing as active ingredients compounds of the arylbenzenesulfonamide-type, and processes for their preparation
JPS611651A (ja)	1984-06-12	1986-01-07	Toyama Chem Co Ltd	Ｎ−アシル酸性アミノ酸ジアミド類およびその製造法並びにそれらを含有する抗潰瘍剤
US4757066A (en)	1984-10-15	1988-07-12	Sankyo Company Limited	Composition containing a penem or carbapenem antibiotic and the use of the same
LU86258A1 (fr)	1986-01-21	1987-09-03	Rech Dermatologiques C I R D S	Composes benzamido aromatique,leur procede de preparation et leur utilisation en medecine humaine ou veterinaire et en cosmetique
USRE35862E (en)	1986-08-18	1998-07-28	Emisphere Technologies, Inc.	Delivery systems for pharmacological agents encapsulated with proteinoids
FR2636238B1 (fr)	1988-09-14	1994-01-21	Morelle Jean	Nouvelles compositions antisudorales
JPH02239980A (ja)	1989-03-15	1990-09-21	Fuji Photo Film Co Ltd	感熱記録材料
US6099856A (en)	1992-06-15	2000-08-08	Emisphere Technologies, Inc.	Active agent transport systems
US5451410A (en)	1993-04-22	1995-09-19	Emisphere Technologies, Inc.	Modified amino acids for encapsulating active agents
US5447728A (en)	1992-06-15	1995-09-05	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
US5714167A (en)	1992-06-15	1998-02-03	Emisphere Technologies, Inc.	Active agent transport systems
US5629020A (en)	1994-04-22	1997-05-13	Emisphere Technologies, Inc.	Modified amino acids for drug delivery
US5541155A (en)	1994-04-22	1996-07-30	Emisphere Technologies, Inc.	Acids and acid salts and their use in delivery systems
US6221367B1 (en)	1992-06-15	2001-04-24	Emisphere Technologies, Inc.	Active agent transport systems
US5443841A (en)	1992-06-15	1995-08-22	Emisphere Technologies, Inc.	Proteinoid microspheres and methods for preparation and use thereof
US5811127A (en)	1992-06-15	1998-09-22	Emisphere Technologies, Inc.	Desferrioxamine oral delivery system
HU211995B (en)	1992-06-30	1996-01-29	Gyogyszerkutato Intezet	Process to prepare novel benzoyl amino acid derivs. and pharmaceutical compns. contg.them
US5583020A (en)	1992-11-24	1996-12-10	Ribozyme Pharmaceuticals, Inc.	Permeability enhancers for negatively charged polynucleotides
US5401516A (en)	1992-12-21	1995-03-28	Emisphere Technologies, Inc.	Modified hydrolyzed vegetable protein microspheres and methods for preparation and use thereof
US5958457A (en)	1993-04-22	1999-09-28	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
US5643957A (en)	1993-04-22	1997-07-01	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6461643B2 (en)	1993-04-22	2002-10-08	Emisphere Technologies, Inc.	Oral drug delivery compositions and methods
US20010003001A1 (en)	1993-04-22	2001-06-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5709861A (en)	1993-04-22	1998-01-20	Emisphere Technologies, Inc.	Compositions for the delivery of antigens
JP4361601B2 (ja)	1993-04-22	2009-11-11	エミスフェアー・テクノロジーズ・インク	経口薬剤移送組成物およびその方法
US5935610A (en)	1993-08-26	1999-08-10	Mclean; Linsey	Composition having buffering properties
IL115693A (en)	1994-10-25	2000-08-13	Revlon Consumer Prod Corp	Cosmetic compositions with improved transfer resistance
US6090958A (en)	1995-03-31	2000-07-18	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5650386A (en) *	1995-03-31	1997-07-22	Emisphere Technologies, Inc.	Compositions for oral delivery of active agents
US5989539A (en)	1995-03-31	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
BR9604880A (pt)	1995-03-31	1998-05-19	Emisphere Tech Inc	Composto composição forma de unidade de dosagem métodos para administração de um agente biologicamente ativo para preparar uma composição para administração de um agente ativo e para preparar um composto e composição farmacológica
US6001347A (en)	1995-03-31	1999-12-14	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5866536A (en)	1995-03-31	1999-02-02	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
AU7072596A (en)	1995-09-11	1997-04-01	Emisphere Technologies, Inc.	Method for preparing omega-aminoalkanoic acid derivatives from cycloalkanones
SI9720025A (sl)	1996-03-29	1999-08-31	Emishphere Technologies, Inc.	Spojine in sestavki za prenos aktivne snovi
IL118657A0 (en)	1996-06-14	1996-10-16	Arad Dorit	Inhibitors for picornavirus proteases
CA2243643A1 (fr)	1996-11-18	1998-05-28	Susan Haas	Procede et composition pour induire une tolerance orale chez les mammiferes
US5804688A (en)	1997-02-07	1998-09-08	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5990166A (en)	1997-02-07	1999-11-23	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
EP1015008B1 (fr)	1997-02-07	2015-08-05	Emisphere Technologies, Inc.	Composes et compositions destines a l'administration d'agents actifs
US6051561A (en)	1997-02-07	2000-04-18	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US5939381A (en)	1997-02-07	1999-08-17	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6060513A (en)	1997-02-07	2000-05-09	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5776888A (en)	1997-02-07	1998-07-07	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5773647A (en)	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5879681A (en)	1997-02-07	1999-03-09	Emisphere Technolgies Inc.	Compounds and compositions for delivering active agents
US5876710A (en)	1997-02-07	1999-03-02	Emisphere Technologies Inc.	Compounds and compositions for delivering active agents
US6313088B1 (en)	1997-02-07	2001-11-06	Emisphere Technologies, Inc.	8-[(2-hydroxy-4-methoxy benzoyl) amino]-octanoic acid compositions for delivering active agents
US6358504B1 (en)	1997-02-07	2002-03-19	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5863944A (en)	1997-04-30	1999-01-26	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US5962710A (en)	1997-05-09	1999-10-05	Emisphere Technologies, Inc.	Method of preparing salicyloylamino acids
AU1804299A (en)	1997-12-08	1999-06-28	Glycomed Incorporated	Sialyl lewis x and sialyl lewis a glycomimetics
WO2000006534A1 (fr)	1998-07-27	2000-02-10	Emisphere Technologies, Inc.	Composes permettant de delivrer des agents actifs et compositions a base de ces composes
US6440929B1 (en)	1998-07-27	2002-08-27	Emisphere Technologies, Inc.	Pulmonary delivery of active agents
EP1102742B1 (fr) *	1998-08-07	2006-06-14	Emisphere Technologies, Inc.	Composes et compositions pour l'administration de principes actifs
EP1146860A4 (fr)	1999-01-08	2002-07-03	Emisphere Tech Inc	Agents d'administration polymeres et composes d'agents d'administration
CA2361716C (fr)	1999-02-05	2009-04-28	Emisphere Technologies, Inc.	Procede de preparation de salicylamides alkyles
MXPA01008611A (es)	1999-02-26	2003-06-24	Emisphere Tech Inc	Compuestos y composiciones para suministrar agentes activos.
AU4218400A (en)	1999-04-05	2000-10-23	Emisphere Technologies, Inc.	Lyophilized solid dosage forms and methods of making
EP1175390B1 (fr)	1999-04-05	2005-02-02	Emisphere Technologies, Inc.	Sels disodiques, monohydrates et solvates ethanol pour liberer des agents actifs
JP2004501057A (ja)	1999-11-05	2004-01-15	エミスフェアー・テクノロジーズ・インク	フェニルアミンカルボン酸化合物及び活性剤を送達するための組成物
AU2274201A (en)	1999-12-16	2001-06-25	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
JP4879433B2 (ja)	2000-01-13	2012-02-22	エミスフェアー・テクノロジーズ・インク	活性剤を送達するための化合物および組成物
US6384278B1 (en)	2000-02-04	2002-05-07	Emisphere Technologies, Inc.	Boron-mediated amidation of carboxylic acids
EP1284724B1 (fr)	2000-03-21	2012-04-18	Emisphere Technologies, Inc.	Procede de preparation de salicylamides alkyles par un agent intermediaire dicarboxylate
AU2001275231A1 (en)	2000-06-02	2001-12-11	Emisphere Technologies, Inc.	Method of preparing salicylamides
DE60134245D1 (de)	2000-09-06	2008-07-10	Emisphere Tech Inc	(5-(2-hydroxy-4-chlorbenzoyl)valeriansäure und deren salze, und zusammensetzungen zur zuführung von wirkstoffen, die diese verbindungen enthalten
MXPA03007837A (es)	2001-03-01	2004-03-16	Emisphere Techonologies Inc	Composiciones para suministrar bisfosfonatos.
EP2308479A3 (fr)	2001-03-01	2012-10-24	Emisphere Technologies, Inc.	Composés et compositions pour la distribution d'agents actifs
AU2002316200A1 (en)	2001-06-08	2002-12-23	Emisphere Technologies, Inc.	Compound and composition for delivering active agents
US7411084B2 (en)	2001-09-26	2008-08-12	Emisphere Technologies, Inc.	Method of preparing phenoxy alkanoic, alkenoic, and alkynoic acids and salts thereof via a dicarboxylate intermediate
EP1453816B1 (fr)	2001-11-13	2013-09-18	Emisphere Technologies, Inc.	Composes phenoxy amine et compositions pour administrer des principes actifs
US20030198666A1 (en)	2002-01-07	2003-10-23	Richat Abbas	Oral insulin therapy
ES2412306T3 (es)	2002-01-09	2013-07-11	Emisphere Technologies, Inc.	Polimorfos de 4-((4-cloro-2-hidroxibenzoil)amino)butanoato de sodio
JP2006519839A (ja) *	2003-03-11	2006-08-31	ファルマシア・コーポレーション	Ｓ−［２−［（１−イミノエチル）アミノ］エチル］−２−メチル−ｌ−システインマレエートｉｉ型結晶塩

2001
- 2001-06-29 ES ES01952394T patent/ES2306719T3/es not_active Expired - Lifetime
- 2001-06-29 DK DK01952394T patent/DK1299348T3/da active
- 2001-06-29 UA UA2003010772A patent/UA80248C2/uk unknown
- 2001-06-29 SK SK118-2003A patent/SK1182003A3/sk unknown
- 2001-06-29 IL IL15329701A patent/IL153297A0/xx unknown
- 2001-06-29 JP JP2002507766A patent/JP2004521857A/ja active Pending
- 2001-06-29 EP EP01952394A patent/EP1299348B1/fr not_active Expired - Lifetime
- 2001-06-29 US US10/312,703 patent/US7351741B2/en not_active Expired - Lifetime
- 2001-06-29 AU AU2001273153A patent/AU2001273153B2/en not_active Ceased
- 2001-06-29 DE DE60133555T patent/DE60133555T2/de not_active Expired - Lifetime
- 2001-06-29 MX MXPA02012855A patent/MXPA02012855A/es active IP Right Grant
- 2001-06-29 NZ NZ523017A patent/NZ523017A/en not_active IP Right Cessation
- 2001-06-29 CA CA002411754A patent/CA2411754C/fr not_active Expired - Lifetime
- 2001-06-29 CN CNB018119182A patent/CN100482637C/zh not_active Expired - Lifetime
- 2001-06-29 PT PT01952394T patent/PT1299348E/pt unknown
- 2001-06-29 AT AT01952394T patent/ATE391708T1/de active
- 2001-06-29 RU RU2003102615/04A patent/RU2326110C2/ru not_active IP Right Cessation
- 2001-06-29 BR BR0112311-4A patent/BR0112311A/pt active Search and Examination
- 2001-06-29 CZ CZ20030275A patent/CZ303736B6/cs not_active IP Right Cessation
- 2001-06-29 KR KR1020027017966A patent/KR100828668B1/ko not_active Expired - Fee Related
- 2001-06-29 AU AU7315301A patent/AU7315301A/xx active Pending
- 2001-06-29 WO PCT/US2001/021073 patent/WO2002002509A1/fr active IP Right Grant
2002
- 2002-12-09 ZA ZA200209946A patent/ZA200209946B/en unknown
2003
- 2003-10-06 HK HK03107183A patent/HK1054918A1/xx not_active IP Right Cessation
2006
- 2006-02-17 AU AU2006200678A patent/AU2006200678B2/en not_active Ceased
2008
- 2008-06-19 CY CY20081100654T patent/CY1108532T1/el unknown

Also Published As

Publication number	Publication date
US20040048777A1 (en)	2004-03-11
ATE391708T1 (de)	2008-04-15
DE60133555T2 (de)	2008-09-18
DK1299348T3 (da)	2008-07-28
JP2004521857A (ja)	2004-07-22
CA2411754A1 (fr)	2002-01-10
UA80248C2 (en)	2007-09-10
EP1299348B1 (fr)	2008-04-09
RU2326110C2 (ru)	2008-06-10
AU2006200678B2 (en)	2009-01-15
CN100482637C (zh)	2009-04-29
ES2306719T3 (es)	2008-11-16
DE60133555D1 (de)	2008-05-21
NZ523017A (en)	2004-10-29
KR20030058958A (ko)	2003-07-07
AU2001273153B2 (en)	2005-11-17
AU2006200678A1 (en)	2006-03-09
AU7315301A (en)	2002-01-14
CZ303736B6 (cs)	2013-04-17
EP1299348A4 (fr)	2005-07-20
BR0112311A (pt)	2003-09-02
CA2411754C (fr)	2009-05-26
IL153297A0 (en)	2003-07-06
CN1460100A (zh)	2003-12-03
AU2001273153C1 (en)	2002-01-14
PT1299348E (pt)	2008-05-12
US7351741B2 (en)	2008-04-01
AU2001273153A2 (en)	2002-01-14
EP1299348A1 (fr)	2003-04-09
WO2002002509A1 (fr)	2002-01-10
KR100828668B1 (ko)	2008-05-09
CY1108532T1 (el)	2014-04-09
MXPA02012855A (es)	2004-04-20
ZA200209946B (en)	2003-11-07
HK1054918A1 (en)	2003-12-19

Publication	Publication Date	Title
SK1182003A3 (en)	2003-09-11	Compounds and compositions for delivering active agents
AU2001273153A1 (en)	2002-04-11	Compounds and compositions for delivering active agents
US7420085B2 (en)	2008-09-02	Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate
EP1102742B1 (fr)	2006-06-14	Composes et compositions pour l'administration de principes actifs
EP1156787B1 (fr)	2005-11-30	Composes a base d'oxadiazole et compositions destinees a l'apport d'agents actifs
JP2004501057A (ja)	2004-01-15	フェニルアミンカルボン酸化合物及び活性剤を送達するための組成物
WO2000050386A1 (fr)	2000-08-31	Composes et compositions pour l'administration de principes actifs
US20060210533A1 (en)	2006-09-21	Compounds and compositions for delivering active agents
IL153297A (en)	2010-04-29	Compounds and compositions for delivering active agents